Daily BriefsIPOs and Placements

Equity Capital Markets: MicroPort CardioFlow and more

In today’s briefing:

  • Microport Cardioflow: Winning in TAVR

Microport Cardioflow: Winning in TAVR

By Kemp Dolliver, CFA

MicroPort Cardioflow Medtech Corporation, a 67%-owned subsidiary of MicroPort Scientific, is a leading medical device company in China. The company’s primary product is VitaFlow, a transcatheter aortic valve implantation (“TAVI” or “TAVR”) device, used to treat Aortic stenosis. TAVR is an emerging medical procedure in China with a handful of competitors at the moment.  The company has filed an Application Proof to list on the HKEX.

This Insight will discuss the company’s products, market opportunity, IP, etc. We will provide more details closer to the offering in a future Insight.

Before it’s here, it’s on Smartkarma